MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

BACKGROUND: The CD133 antigen is a marker of radio- and chemo-resistant stem cell populations in glioblastoma (GBM). The O(6)-methylguanine DNA methyltransferase (MGMT) enzyme is related with temozolomide (TMZ) resistance. Our propose is to analyze the prognostic significance of the CD133 antigen an...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Melguizo, Consolación, Prados, Jose, González, Beatriz, Ortiz, Raul, Concha, Angel, Alvarez, Pablo Juan, Madeddu, Roberto, Perazzoli, Gloria, Oliver, Jaime Antonio, López, Rodrigo, Rodríguez-Serrano, Fernando, Aránega, Antonia
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2012
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3551841/
https://ncbi.nlm.nih.gov/pubmed/23245659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-10-250
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia